38 research outputs found

    The local control rate, disease-free survival (DFS), and overall survival (OS) of the cohort (Fig. 2A: local control rate, Fig. 2B: DFS, Fig. 2C: OS).

    No full text
    <p>The local control rate, disease-free survival (DFS), and overall survival (OS) of the cohort (Fig. 2A: local control rate, Fig. 2B: DFS, Fig. 2C: OS).</p

    Univariate analyses of overall survival, local control, and disease-free survival.

    No full text
    <p>Univariate analyses of overall survival, local control, and disease-free survival.</p

    Cumulative incidence of Grade 3+ acute complications to NCI CTC 3.0 (during ACT and CRT).

    No full text
    <p>Cumulative incidence of Grade 3+ acute complications to NCI CTC 3.0 (during ACT and CRT).</p

    Patient characteristics.

    No full text
    *<p>: CRT: concurrent chemoradiotherapy;</p>†<p>: ACT: adjuvant chemotherapy;</p><p>LN: lymph nodes;</p>††<p>: American Joint Committee on Cancer;</p>§<p>: R0: no residual tumor after resection;</p>∥<p>:R1: microscopic residual tumor after resection;</p>¶<p>:D2: removal of all invaded N2 lymph nodes:</p>#<p>:D1:removal of all invaded N1 lymph nodes;</p><p>CCT: concurrent chemotherapy.</p

    Phylogenetic analysis based on the 5’-UTR region of HFMD cases during 2009 to June 2013 in Jinan, China.

    No full text
    <p>A total of 29 representative sequences (representing 12 serotypes) from this study and 12 reference strains worldwide were used to build the tree. Jinan sequences were labeled by black solid dot. Abbreviations: JN, Jinan; CHN, China.</p
    corecore